Tuning peptide specifities for T cell tolerance in Type 1 diabetes
调整 1 型糖尿病 T 细胞耐受性的肽特异性
基本信息
- 批准号:10630946
- 负责人:
- 金额:$ 46.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAddressAdoptive TransferAffectAffinityAgonistAmino AcidsAntibodiesAntigensAutoantigensAutoimmune DiseasesAutoimmunityBacterial Artificial ChromosomesBindingBiochemical PathwayBlood GlucoseCD4 Positive T LymphocytesCellsCharacteristicsClonal DeletionCollaborationsCouplingDataDevelopmentDiabetes MellitusDiabetes preventionDiseaseDisease OutcomeEpitopesFutureGenerationsGenesHistocompatibility Antigens Class IIImmune ToleranceImmunotherapyInbred NOD MiceInsulinInsulin-Dependent Diabetes MellitusKnock-inKnowledgeLaboratoriesMHC Class II GenesMediatingModelingMusMutationPathogenicityPeptide/MHC ComplexPeptidesPeripheralPositioning AttributePreventionRegulatory T-LymphocyteRoleSpecificityT-Cell Immunologic SpecificityT-LymphocyteT-cell receptor repertoireTNFSF11 geneTestingTherapeuticTherapeutic InterventionThymus GlandTimeTransgenic MiceTransgenic ModelTransgenic OrganismsVariantWorkanergyautoreactive T cellautoreactivitycentral tolerancediabetes pathogenesiseffector T cellexperienceexperimental studygenetic associationgenome wide association studyimmunoregulationimprovedinsightinsulitisinvariant chainmouse modelnovelperipheral tolerancepreventpromotersingle cell sequencingthymus transplantationtooltranslational potential
项目摘要
Project Summary/Abstract
Type 1 Diabetes (T1D) is a classical T-cell mediated autoimmune disease and substantial data implicates
insulin as a dominant autoantigen in T1D disease. In the NOD mouse model of T1D, notable studies have shown
that mice lacking native insulin expression, but with an altered insulin sequence to maintain blood glucose levels,
are completely protected from insulitis and diabetes. Growing evidence also indicates that insulin peptide binding
and orientation within MHC Class II (peptide register) is important in determining the strength of interaction and
recognition by autoreactive T cells. In collaboration with the Kappler lab, we have uncovered an unusual peptide
binding characteristic of the dominant insulin epitope InsB:9-23. The majority of InsB:9-23-specific CD4+ T cells
in the periphery recognize insulin bound in this unusual register 3, and by knocking in a single amino acid
variation (R to E) into just one copy of the insulin gene in NOD mice (Ins2EE/+), the mice are completely protected
against diabetes.
The development of a “super agonist” version of the insulin dominant epitopes allows us to address several
key questions surrounding the biochemical pathways of peptide generation, presentation by MHC molecules,
and recognitions by auto-reactive pathogenic T cells. Do mutations of the major epitope in the insulin gene allow
CD4+ T effectors or Treg cells specific for these alternative epitopes to develop? Are mimotopes of these
pathogenic epitopes capable of dramatically altering disease outcomes? Are we able to fine tune these epitopes
to alter tolerance mechanisms to shift from deletion to Treg induction? Recent work in our lab has focused on
the identification of the insulin-specific repertoire on key mouse backgrounds, and we plan to utilize these tools
and well-characterized mouse models to examine the effects of altering insulin expression, thymically and
extrathymically. These tools as well as our experience with the generation of numerous TCR-transgenic mouse
lines will allow us to address these questions in the context of T1D.
Thus, we hypothesize that alterations to epitope presentation and TCR affinity drive the tunning of
the TCR repertoire towards tolerance and away from self-reactivity. Using Insulin as a model antigen, we
propose to test our hypothesis through the following specific aims:
Aim 1: Define the role of central tolerance upon the deletion of insulin-reactive clones
Aim 2: Characterize the effects of peripheral tolerance on insulin-reactive T cells
Aim 3: Explore mechanisms of dominate tolerance to understand the potential for translation into
therapeutic treatments for T1D
Through these experiments, we hope to gain a nuanced understanding of how changes in insulin epitopes and
antigenicity drive the pathogenesis of diabetes and identify targets for future immune modulation and
therapeutic intervention for T1D treatment and prevention.
项目总结/摘要
1型糖尿病(T1 D)是一种典型的T细胞介导的自身免疫性疾病,大量数据表明
胰岛素作为T1 D疾病中的显性自身抗原。在T1 D的NOD小鼠模型中,值得注意的研究表明,
缺乏天然胰岛素表达的小鼠,但具有改变的胰岛素序列以维持血糖水平,
完全不受胰岛炎和糖尿病的影响越来越多的证据也表明胰岛素肽结合
在MHC II类(肽寄存器)内的方向和取向在确定相互作用的强度方面是重要的,
通过自身反应性T细胞识别。与Kappler实验室合作,我们发现了一种不寻常的肽
优势胰岛素表位InsB的结合特征:9-23。大多数InsB:9-23特异性CD 4 + T细胞
在外周识别胰岛素结合在这个不寻常的寄存器3,并通过敲入一个氨基酸,
在NOD小鼠(Ins 2 EE/+)中,仅将胰岛素基因的一个拷贝变异(R至E)转化为胰岛素基因的一个拷贝,小鼠完全受到保护
对抗糖尿病
胰岛素优势表位的“超级激动剂”版本的开发使我们能够解决几个问题,
围绕肽生成的生化途径,MHC分子的呈递,
和自身反应性致病性T细胞的免疫抑制。胰岛素基因中主要表位的突变
CD 4 + T效应细胞或Treg细胞特异性这些替代表位发展?是这些的模拟表位
能够显著改变疾病结果的致病性表位?我们是否能够微调这些表位
改变耐受机制,从缺失转变为Treg诱导?我们实验室最近的工作集中在
在关键小鼠背景上识别胰岛素特异性库,我们计划利用这些工具
和良好表征的小鼠模型,以检查改变胰岛素表达的影响,胸腺和
胸腺外的这些工具以及我们在产生大量TCR转基因小鼠方面的经验,
线将使我们能够在T1 D的背景下解决这些问题。
因此,我们假设,表位呈递和TCR亲和力的改变驱动了TCR的调节。
TCR库朝向耐受性和远离自身反应性。使用胰岛素作为模型抗原,我们
建议通过以下具体目标来检验我们的假设:
目的1:明确胰岛素反应性克隆缺失后中枢耐受的作用
目的2:描述外周耐受对胰岛素反应性T细胞的影响
目的3:探索显性耐受的机制,以了解将其转化为
T1 D的治疗
通过这些实验,我们希望能够对胰岛素表位的变化以及
抗原性驱动糖尿病的发病机制,并确定未来免疫调节的靶点,
T1 D治疗和预防的治疗干预。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark S Anderson其他文献
The sickness unto Deaf
致聋之病
- DOI:
10.1038/ni0909-934 - 发表时间:
2009-09-01 - 期刊:
- 影响因子:27.600
- 作者:
James M Gardner;Mark S Anderson - 通讯作者:
Mark S Anderson
Mark S Anderson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark S Anderson', 18)}}的其他基金
Project 2: STAT3 as a trigger for T1D
项目 2:STAT3 作为 T1D 的触发因素
- 批准号:
10576386 - 财政年份:2022
- 资助金额:
$ 46.85万 - 项目类别:
STAT3 variants as a rheostat of immune tolerance
STAT3 变体作为免疫耐受的变阻器
- 批准号:
10328097 - 财政年份:2022
- 资助金额:
$ 46.85万 - 项目类别:
Alterations of leukocyte integrin signaling leading to diabetes and autoimmunity
白细胞整合素信号的改变导致糖尿病和自身免疫
- 批准号:
10502136 - 财政年份:2022
- 资助金额:
$ 46.85万 - 项目类别:
Project 2: STAT3 as a trigger for T1D
项目 2:STAT3 作为 T1D 的触发因素
- 批准号:
10328102 - 财政年份:2022
- 资助金额:
$ 46.85万 - 项目类别:
Tuning peptide specifities for T cell tolerance in Type 1 diabetes
调整 1 型糖尿病 T 细胞耐受性的肽特异性
- 批准号:
10503923 - 财政年份:2022
- 资助金额:
$ 46.85万 - 项目类别:
Alterations of leukocyte integrin signaling leading to diabetes and autoimmunity
白细胞整合素信号的改变导致糖尿病和自身免疫
- 批准号:
10683384 - 财政年份:2022
- 资助金额:
$ 46.85万 - 项目类别:
STAT3 variants as a rheostat of immune tolerance
STAT3 变体作为免疫耐受的变阻器
- 批准号:
10576375 - 财政年份:2022
- 资助金额:
$ 46.85万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 46.85万 - 项目类别:
Research Grant